CRISPR/Cas9 from bench to bedside: What clinicians need to know before application?

Your Location：

Home >

Browse articles >

CRISPR/Cas9 from bench to bedside: What clinicians need to know before application?

LETTER TO THE EDITOR | Updated：2023-02-28

- CRISPR/Cas9 from bench to bedside: What clinicians need to know before application?
- Military Medical Research Vol. 8, Issue 3, Pages: 450-452(2021)
- Affiliations：
  
  1.Department of Joint Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
  2.Department of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  3.Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China
- Author bio：
  
  * ziqingli@upenn.edu; ziqingli@vip.qq.com
- Funds：
- DOI：10.1186/s40779-020-00292-2
  CLC：
- Published：2021-09
- Accepted：
Scan QR Code
Li et al.: CRISPR/Cas9 from bench to bedside: What clinicians need to know before application?. Mil Med Res, 2020, 7: 61.
DOI：

Li et al.: CRISPR/Cas9 from bench to bedside: What clinicians need to know before application?. Mil Med Res, 2020, 7: 61. DOI： 10.1186/s40779-020-00292-2.

摘要

Abstract

In October 2020

Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing using the CRISPR technology. Although CRISPR technology has developed rapidly in the last decade

there are still many uncertainties before eventual use in clinical settings. In this mini review

we summarize the current efforts in addressing the limitations of CRISPR technology and future directions.

关键词

Keywords

references

Lander ES . The heroes of CRISPR . Cell . 2016 ; 164 ( 1–2 ): 18 - 28 .

Dort EN , Tanguay P , Hamelin RC . CRISPR/Cas9 gene editing: an unexplored frontier for forest pathology . Front Plant Sci . 2020 ; 11 : 1126 .

Uddin F , Rudin CM , Sen T . CRISPR gene therapy: applications, limitations, and implications for the future . Front Oncol . 2020 ; 10 : 1387 .

Yang X . Applications of CRISPR-Cas9 mediated genome engineering . Mil Med Res . 2015 ; 2 : 11 .

Li CX , Qian HL . A double-edged sword: CRISPR-Cas9 is emerging as a revolutionary technique for genome editing . Mil Med Res . 2015 ; 2 : 25 .

Hsu MN , Chang YH , Truong VA , Lai PL , Nguyen TKN , Hu YC . CRISPR technologies for stem cell engineering and regenerative medicine . Biotechnol Adv . 2019 ; 37 ( 8 ): 107447 .

Zuccaro MV , Xu J , Mitchell C , Marin D , Zimmerman R , Rana B , et al . Allele-specific chromosome removal after Cas9 cleavage in human embryos . Cell . 2020 ; 183 ( 6 ): 1650-4. e15 .

Kleinstiver BP , Prew MS , Tsai SQ , Topkar VV , Nguyen NT , Zheng Z , et al . Engineered CRISPR-Cas9 nucleases with altered PAM specificities . Nature . 2015 ; 523 ( 7561 ): 481 - 5 .

Manghwar H , Li B , Ding X , Hussain A , Lindsey K , Zhang X , et al . CRISPR/Cas systems in genome editing: methodologies and tools for sgRNA design, offtarget evaluation, and strategies to mitigate off-target effects . Adv Sci (Weinh) . 2020 ; 7 ( 6 ): 1902312 .

Liu L , Yin M , Wang M , Wang Y . Phage AcrIIA2 DNA mimicry: Structural basis of the CRISPR and anti-CRISPR arms race . Mol Cell . 2019 ; 73 ( 3 ): 611-20.e3 .

Shin J , Jiang F , Liu JJ , Bray NL , Rauch BJ , Baik SH , et al . Disabling Cas9 by an anti-CRISPR DNA mimic . Sci Adv . 2017 ; 3 ( 7 ): e1701620 .

Singh K , Evens H , Nair N , Rincon MY , Sarcar S , Samara-Kuko E , et al . Efficient in vivo liver-directed gene editing using CRISPR/Cas9 . Mol Ther . 2018 ; 26 ( 5 ): 1241 - 54 .

Lu J , Zhao C , Zhao Y , Zhang J , Zhang Y , Chen L , et al . Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing . Nucleic Acids Res . 2018 ; 46 ( 5 ): e25 .

Bourgeois JS , Smith CM , Ko DC . These are the genes you're looking for: finding host resistance genes . Trends Microbiol . 2020 ; 29 ( 4 ): 346 - 62 .

Xu X , Wan T , Xin H , Li D , Pan H , Wu J , et al . Delivery of CRISPR/Cas9 for therapeutic genome editing . J Gene Med . 2019 ; 21 ( 7 ): e3107 .

0

Views

0

Downloads

0

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Related Articles

Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges

Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research

Applications of CRISPR-Cas9 mediated genome engineering

Fracture Load Test and Spatial Analysis for the Full Scale Model of Underground Viaduct Channel Girder

Experimental Research on the Maximum Tensile Force in Reinforced Abutment Reinforcement

Related Author

Mohammed Fatih Rasul

Mohammad Taheri

Wojciech Branicki

Mark C. Glassy

Milladur Rahman

Soudeh Ghafouri-Fard

Aria Baniahmad

Abbas Salihi

Related Institution

Department of Medical Laboratory Science, Komar University of Science and Technology

Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences

Faculty of Biology, Institute of Zoology and Biomedical Research, Jagiellonian University

Translational Neuro-Oncology Laboratory, San Diego (UCSD) Moores Cancer Center, University of California

Department of Clinical Sciences, Malmö, Section for Surgery, Lund University

⁰